Cel-Sci Corporation - CVM
The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.
One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.
Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.
 |
|
Latest Newsletter Editions Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...
Click Here For More Newsletters on CVM | |
Latest Blog Entries |
Quote Data
|
|
Business Summary
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.
Disclosure
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.
Recent News Headlines
Fri, 17 May 2013 17:04:39 GMT
Fri, 10 May 2013 20:35:00 GMT
[Business Wire] - CEL-SCI Corporation reports financial results for the fiscal quarter ended March 31, 2013.
Fri, 10 May 2013 13:31:07 GMT
Mon, 06 May 2013 12:34:36 GMT
Mon, 06 May 2013 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis using the LEAPS technology , which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics.
Fri, 03 May 2013 14:55:05 GMT
[at noodls] - CEL-SCI TO PRESENT AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS 100TH ANNUAL MEETING ON SATURDAY MAY 4TH Vienna, VA, May 3, 2013 -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that it will deliver ...
Fri, 03 May 2013 13:11:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it will deliver a presentation at the American Association of Immunologists 100th Annual Meeting at the Hawaii Convention Center in Honolulu, Hawaii.
Fri, 26 Apr 2013 12:15:00 GMT
Wed, 24 Apr 2013 11:01:00 GMT
[Marketwired] - In newly published news, CEL-SCI Corporation has provided investors a much needed update on the Phase III Clinical Trial of its investigational drug Multikine.
Tue, 23 Apr 2013 12:05:00 GMT
Tue, 23 Apr 2013 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today provided an update on the Phase III Clinical Trial of its investigational drug Multikine* for the treatment of head and neck cancer.
Tue, 16 Apr 2013 10:17:19 GMT
Mon, 08 Apr 2013 19:11:00 GMT
Mon, 08 Apr 2013 16:55:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that its collaborators at the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health, USA, have submitted for publication to a prestigious scientific journal the results from efficacy studies in animals of L.E.A.P.S.
Thu, 04 Apr 2013 11:01:00 GMT
[Marketwired] - Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released ...
Tue, 02 Apr 2013 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it has released a new video about its investigational cancer drug Multikine* and the dedicated manufacturing facility to produce Multikine near Baltimore, MD, USA.
Thu, 28 Mar 2013 13:15:09 GMT
Mon, 04 Mar 2013 18:39:20 GMT
[Marketwired] - Taglich Brothers, Inc. announces it initiated coverage of CEL-SCI Corporation.
Mon, 25 Feb 2013 15:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has added two additional Taiwanese clinical centers in CEL-SCI’s Phase III head and neck cancer clinical trial for Multikine® , the Company’s flagship investigational immunotherapy.
Fri, 08 Feb 2013 23:29:46 GMT
[at noodls] - CEL-SCI CORPORATION REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Vienna, VA, February 8, 2013 -- CEL-SCI Corporation (NYSE MKT: CVM) reports financial results for the fiscal quarter ended December 31, ...